UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________to__________

Commission File Number: 001-41002

Tevogen Bio Holdings Inc.

(Exact name of registrant as specified in its charter)

Delaware		98-1597194
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

15 Independence Boulevard, Suite #210 Warren, New Jersey		07059
(Address of principal executive offices)		(Zip Code)

(877) 838-6436

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	TVGN	The Nasdaq Stock Market LLC
Warrants, each exercisable for one share of Common Stock for $11.50 per share	TVGNW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☒	Smaller reporting company	☒

Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

As of August 13, 2025, there were 196,705,067 shares of the registrant’s common stock, par value $0.0001 per share, outstanding.

Table of Contents

	Page
Part I - Financial Information	1
Item 1. Financial Statements (Unaudited).	1
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.	20
Item 3. Quantitative and Qualitative Disclosures About Market Risk.	34
Item 4. Controls and Procedures.	34
Part II - Other Information	35
Item 1. Legal Proceedings.	35
Item 1A. Risk Factors.	35
Item 5. Other Information.	36
Item 6. Exhibits.	37
Signatures	38

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

TEVOGEN BIO HOLDINGS INC.

UNAUDITED CONSOLIDATED BALANCE SHEETS

	June 30,			December 31,
	2025			2024
Assets
Current assets:
Cash	$	685,229		$	1,282,995
Prepaid expenses and other assets		1,216,851			919,088
Due from related party		158,819			158,819
Total current assets		2,060,899			2,360,902

Property and equipment, net		164,448			296,442
Right-of-use assets - operating leases		1,477,905			228,490
Other assets		565,884			575,841
Total assets	$	4,269,136		$	3,461,675

Liabilities and stockholders’ deficit
Current liabilities:
Accounts payable	$	4,240,302		$	5,200,245
Accrued expenses and other liabilities		1,612,920			1,712,396
Operating lease liabilities		327,740			229,063
Notes payable		1,651,000			1,651,000
Due to related party		250,000			250,000
Total current liabilities		8,081,962			9,042,704

Loan agreement		4,400,000			1,000,000
Operating lease liabilities		1,177,183			5,796
Derivative warrant liabilities		94,733			87,180
Total liabilities		13,753,878			10,135,680

Stockholders’ deficit
Series A Preferred Stock, $0.0001 par value; 2,000 shares authorized; 500 shares issued and outstanding as of June 30, 2025 and December 31, 2024 (liquidation value of $2,076,712 at June 30, 2025)		2,799,990			2,799,990
Series C Preferred Stock, $0.0001 par value; 600 shares authorized; 600 shares issued and outstanding as of June 30, 2025 and December 31, 2024 (liquidation value of $6,082,603 at June 30, 2025)		6,000,000			6,000,000
Preferred Stock, value		6,000,000			6,000,000
Common stock, $0.0001 par value; 800,000,000 shares authorized; 193,693,433 and 177,991,365 shares issued and outstanding at June 30, 2025 and December 31, 2024		19,370			17,800
Additional paid-in capital		110,952,055			97,893,322
Accumulated deficit		(129,256,157	)		(113,385,117	)
Total stockholders’ deficit		(9,484,742	)		(6,674,005	)
Total liabilities and stockholders’ deficit	$	4,269,136		$	3,461,675

See accompanying notes to the unaudited consolidated financial statements.

TEVOGEN BIO HOLDINGS INC.

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS

	2025			2024			2025			2024
	Three months ended June 30,						Six months ended June 30,
	2025			2024			2025			2024
Operating expenses:
Research and development	$	2,699,991		$	4,124,450		$	5,895,059		$	24,936,032
General and administrative		2,744,545		$	4,474,577			9,905,824			13,179,719
Total operating expenses		5,444,536			8,599,027			15,800,883			38,115,751
Loss from operations		(5,444,536	)		(8,599,027	)		(15,800,883	)		(38,115,751	)
Interest (expense) income, net		(38,033	)		6			(62,604	)		(155,780	)
Merger transaction costs		—			—			—			(7,499,353	)
Change in fair value of warrants		(21,410	)		38,788			(7,553	)		6,815
Change in fair value of convertible promissory notes		—			—			—			48,468,678
Change in fair value of written call option derivative liabilities		—			(213,214	)		—			(213,214	)
Loss on issuance of commitment shares		—			(890,000	)		—			(890,000	)
Net (loss) income	$	(5,503,979	)	$	(9,663,447	)	$	(15,871,040	)	$	1,601,395

Net (loss) income attributable to common stockholders, basic	$	(5,641,102	)	$	(6,075,379	)	$	(16,145,287	)	$	5,044,907
Net loss attributable to common stockholders, diluted	$	(5,641,102	)	$	(6,075,379	)	$	(16,145,287	)	$	(43,124,798	)
Net (loss) income per share attributable to common stockholders, basic	$	(0.03	)	$	(0.04	)	$	(0.09	)	$	0.03
Net loss per share attributable to common stockholders, diluted	$	(0.03	)	$	(0.04	)	$	(0.09	)	$	(0.29	)
Weighted-average common stock outstanding, basic		184,307,169			154,167,090			182,541,433			145,655,205
Weighted-average common stock outstanding, diluted		184,307,169			154,167,090			182,541,433			148,154,361

See accompanying notes to the unaudited consolidated financial statements.

TEVOGEN BIO HOLDINGS INC.

UNAUDITED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Capital			Deficit			Deficit
	Series A Preferred Stock				Series B Preferred Stock				Series C Preferred Stock				Common Stock				Additional Paid-in			Accumulated			Total Stockholders’
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Capital			Deficit			Deficit
Balance at January 1, 2025		500	$	2,799,990		—		—		600	$	6,000,000		177,991,365	$	17,800	$	97,893,322		$	(113,385,117	)	$	(6,674,005	)
Issuance of common stock in settlement of vested restricted stock units		—		—		—		—		—		—		5,902,068		590		(590	)		—			—
Loan agreement interest settled in stock		—		—		—		—		—		—		—		—		28,269			—			28,269
Capital contribution		—		—		—		—		—		—		—		—		2,000,000			—			2,000,000
Stock-based compensation		—		—		—		—		—		—		—		—		7,292,701			—			7,292,701
Net loss		—		—		—		—		—		—		—		—		—			(10,367,061	)		(10,367,061	)
Balance at March 31, 2025		500	$	2,799,990		—		—		600	$	6,000,000		183,893,433	$	18,390	$	107,213,702		$	(123,752,178	)	$	(7,720,096	)
Issuance of common stock in settlement of vested restricted stock units		—		—		—		—		—		—		9,800,000		980		(980	)		—			—
Capital contribution		—		—		—		—		—		—		—		—		500,000			—			500,000
Stock-based compensation		—		—		—		—		—		—		—		—		3,239,333			—			3,239,333
Net loss		—		—		—		—		—		—		—		—		—			(5,503,979	)		(5,503,979	)
Balance at June 30, 2025		500	$	2,799,990		—		—		600	$	6,000,000		193,693,433		19,370		110,952,055			(129,256,157	)		(9,484,742	)

	Shares		Amount		Shares			Amount			Shares		Amount		Capital			Deficit			Deficit
	Series A Preferred Stock				Series B Preferred Stock						Common Stock				Additional Paid-in			Accumulated			Total Stockholders’
	Shares		Amount		Shares			Amount			Shares		Amount		Capital			Deficit			Deficit
Balance at January 1, 2024		—	$	—		—			—			119,999,989	$	12,000	$	5,216,840		$	(99,657,737	)	$	(94,428,897	)
Issuance of Series A preferred stock		500		2,799,990		—			—			—		—		—			—			2,799,990
Nonrefundable prepaid proceeds towards anticipated Series A-1 preferred stock issuance		—		—		—			—			—		—		200,000			—			200,000
Issuance of Series B preferred stock		—		—		3,613			3,613,000			—		—		—			—			3,613,000
Conversion of convertible promissory notes into common stock in connection with merger		—		—		—			—			10,337,419		1,034		46,621,593			—			46,622,627
Merger, net of redemptions and transaction costs		—		—		—			—			14,778,056		1,478		(2,885,459	)		—			(2,883,981	)
Issuance of restricted common stock		—		—		—			—			19,348,954		1,935		(1,935	)		—			—
Issuance of common stock for Sponsor advisory service fee		—		—		—			—			150,000		15		676,485			—			676,500
Stock-based compensation		—		—		—			—			—		—		26,333,249			—			26,333,249
Net income		—		—		—			—			—		—		—			11,264,842			11,264,842
Balance at March 31, 2024		500	$	2,799,990		3,613			3,613,000			164,614,418	$	16,462	$	76,160,773		$	(88,392,895	)	$	(5,802,670	)
Balance		500	$	2,799,990		3,613			3,613,000			164,614,418	$	16,462	$	76,160,773		$	(88,392,895	)	$	(5,802,670	)
Issuance of commitment shares in connection with the loan agreement		—		—		—			—			1,000,000		100		889,900			—			890,000
Issuance of common stock in connection with Polar Note payable		—		—		—			—			1,500,000		150		(150	)		—			—
Issuance of common stock in settlement of vested restricted stock units		—		—		—			—			1,711,984		171		(171	)		—			—
Nonrefundable prepaid proceeds towards anticipated Series A-1 preferred stock issuance		—		—		—			—			—		—		2,800,000			—			2,800,000
Repurchase of Series B preferred stock		—		—		(3,613	)		(3,613,000	)		—		—		3,613,000			—			—
Stock-based compensation		—		—		—			—			—		—		4,142,220			—			4,142,220
Net loss		—		—		—			—			—		—		—			(9,663,447	)		(9,663,447	)
Net income (loss)		—		—		—			—			—		—		—			(9,663,447	)		(9,663,447	)
Balance at June 30, 2024		500	$	2,799,990		—		$	—			168,826,402	$	16,883	$	87,605,572			(98,056,342	)		(7,633,897	)
Balance		500	$	2,799,990		—		$	—			168,826,402	$	16,883	$	87,605,572			(98,056,342	)		(7,633,897	)

See accompanying notes to the unaudited consolidated financial statements.

TEVOGEN BIO HOLDINGS INC.

UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS

	2025			2024
	For the six months ended June 30,
	2025			2024
Cash flows from operating activities:
Net (loss) income	$	(15,871,040	)	$	1,601,395
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation expense		131,994			81,104
Stock-based compensation expense		10,532,034			30,475,469
Non-cash interest expense		—			159,305
Merger transaction costs		—			7,099,353
Change in fair value of convertible promissory notes		—			(48,468,678	)
Loss on Series A Preferred Stock issuance		—			799,990
Loss on issuance of commitment shares		—			890,000
Change in fair value of warrants		7,553			(6,815	)
Issuance of written call option		—			375,000
Change in fair value of written call option derivative liabilities		—			(161,786	)
Amortization of right-of-use asset		264,192			117,189
Change in operating assets and liabilities:
Prepaid expenses and other assets		(297,763	)		(479,471	)
Other assets		9,957			(68,446	)
Accounts payable		(959,943	)		3,151,676
Accrued expenses and other liabilities		(71,206	)		(589,529	)
Operating lease liabilities		(243,544	)		(122,091	)
Net cash used in operating activities		(6,497,766	)		(5,146,335	)
Cash flows from investing activities:
Purchases of property and equipment		—			—
Net cash used in investing activities		—			—
Cash flows from financing activities:
Cash acquired in connection with the reverse recapitalization		—			229,328
Proceeds from issuance of Series A Preferred Stock		—			2,000,000
Nonrefundable prepaid proceeds towards anticipated Series A-1 Preferred Stock Issuance		—			3,000,000
Capital contribution		2,500,000			—
Proceeds from loan agreement		3,400,000			—
Net cash provided by financing activities		5,900,000			5,229,328
Net (decrease) increase in cash		(597,766	)		82,993
Cash – beginning of period		1,282,995			1,052,397
Cash – end of period	$	685,229		$	1,135,390
Supplementary disclosure of noncash investing and financing activities:
Conversion of convertible promissory notes into common stock in connection with Merger		—			46,622,627
Repurchase of Series B preferred stock		—			3,613,000
Issuance of common stock for net liabilities upon reverse recapitalization, net of transaction costs		—			(3,113,309	)
Right-of-use assets obtained in exchange for operating lease liabilities		1,513,607			—

See accompanying notes to the unaudited consolidated financial statements.

TEVOGEN BIO HOLDINGS INC.

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1. NATURE OF BUSINESS

Tevogen Bio Holdings Inc., a Delaware corporation (the “Company”), is a clinical-stage specialty immunotherapy company harnessing the power of CD8+ cytotoxic T lymphocytes to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The Company’s precision T cell technology, ExacTcell, is a set of processes and methodologies to develop, enrich, and expand single human leukocyte antigen-restricted CTL therapies with proactively selected, precisely defined targets. The Company has completed a Phase 1 proof-of-concept trial for the first clinical product of ExacTcell, TVGN 489, for the treatment of ambulatory, high-risk adult COVID-19 patients, and has other product candidates in its pipeline.

In addition, through the Company’s Tevogen.AI artificial intelligence (“AI”) initiative, it is focused on harnessing the potential of AI to expedite drug development, optimize laboratory processes and clinical trials, unravel complex biological data, improve patient outcomes, and pass on related savings to patients.

On February 14, 2024 (the “Closing Date”), pursuant to the Agreement and Plan of Merger dated June 28, 2023 (the “Merger Agreement”) by and among Semper Paratus Acquisition Corporation (“Semper Paratus”), Semper Merger Sub, Inc., a wholly owned subsidiary of Semper Paratus (“Merger Sub”), SSVK Associates, LLC (the “Sponsor”), Tevogen Bio Inc (n/k/a Tevogen Bio Inc.) (“Tevogen Bio”), and Dr. Ryan Saadi, in his capacity as seller representative, Merger Sub merged with and into Tevogen Bio, with Tevogen Bio being the surviving entity and a wholly owned subsidiary of Semper Paratus (the “Merger” and together with the other transactions contemplated by the Merger Agreement, the “Business Combination”), and Semper Paratus was renamed Tevogen Bio Holdings Inc.

In connection with the closing of the Business Combination (the “Closing”), the then-outstanding shares of common stock of Tevogen Bio were converted into shares of the common stock of the Company at an exchange ratio of approximately 4.85 shares of Company common stock for each share of Tevogen Bio common stock (the “Exchange Ratio”). See Note 4 for more information on the Business Combination.

As discussed in Note 4, the Merger was accounted for as a reverse recapitalization under which the historical financial statements of the Company prior to the Merger are those of Tevogen Bio. All information related to the common stock of Tevogen Bio prior to the Closing and presented in the unaudited consolidated financial statements and notes thereto has been retroactively adjusted to reflect the Exchange Ratio.

Following the Merger, the former equity holders and holders of convertible promissory notes of Tevogen Bio held 91.0% of the outstanding shares of common stock of the Company and the former shareholders, creditors, and other contractual counterparties of Semper Paratus held 9.0% of the Company.

NOTE 2. DEVELOPMENT-STAGE RISKS AND LIQUIDITY

The Company has generally incurred losses and negative cash flows from operations since inception. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales from its product candidates currently in development. Management believes that cash of $685,229 as of June 30, 2025, net proceeds through August 13, 2025 of $2,533,023 pursuant to the Sales Agreement (as defined in Note 13), and a capital contribution of $1,000,000 from KRHP LLC, a New Jersey limited liability company (“KRHP”), received in August 2025, combined with the amounts available under the Loan Agreement (as defined in Note 7) entered into in June 2024, and the remaining commitment for a $7,000,000 grant from KRHP, will allow the Company to have adequate cash and financial resources to operate for at least the next 12 months from the date of issuance of these unaudited consolidated financial statements. The Company does not plan to initiate a clinical trial until additional funding is received.

TEVOGEN BIO HOLDINGS INC.

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Management regularly evaluates different strategies to obtain funding for operations for subsequent periods. These strategies may include but are not limited to private placements of securities, licensing and/or marketing arrangements, partnerships with other pharmaceutical or biotechnology companies, and public offerings of securities. The Company may not be able to obtain financing on acceptable terms and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. If the Company is unable to obtain sufficient funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion, or future commercialization efforts, which could adversely affect its business prospects.

Operations since inception have consisted primarily of organizing the Company, securing financing, developing licensed technologies, performing research, conducting pre-clinical studies and a clinical trial, pursuing related business opportunities, and pursuing and completing the Business Combination. The Company is subject to risks associated with any specialty biotechnology company that requires considerable expenditures for research and development. The Company’s research and development and other projects may not be successful, products developed may not obtain necessary regulatory approval, and any approved product may not be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.

NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The summary of significant accounting policies in Note 3 to the Company’s audited consolidated financial statements included in the Annual Report on Form 10-K filed with the SEC on April 2, 2025 have not materially changed, except as reflected in the following:

Basis of Presentation

These unaudited consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). In the opinion of management, all adjustments considered necessary for a fair statement of the financial position and results of operations of the Company have been included.

Segment Reporting

Operating segments are defined as components of an entity for which discrete financial information is both available and regularly reviewed by its chief operating decision maker or decision-making group. The Company views its operations and manages its business in one segment. As part of new requirements under ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), the Company has included enhanced footnotes within its quarterly reporting—see Note 11.

Fair Value Measurements

Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the price that would be received for an asset or paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:

Level 1	Unadjusted quoted prices in active markets for identical assets or liabilities;

Level 2	Observable inputs other than Level 1 prices, such as quoted prices for similar, but not identical, assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data;

Level 3	Unobservable inputs in which there is little or no market data available and which require the Company to develop its own assumptions that market participants would use in pricing an asset or liability.

TEVOGEN BIO HOLDINGS INC.

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Financial instruments recognized at historical amounts in the balance sheets consist of accounts payable and notes payable. The Company believes that the carrying value of accounts payable and notes payable approximates their fair values due to the short-term nature of these instruments.

The Company’s recurring fair value measurements consist of the convertible promissory notes prior to the Merger, for which the Company elected the fair value option to reduce accounting complexity, and private warrants after the Merger. Such fair value measurements are Level 3 inputs. The following table provides a roll-forward of the aggregate fair values of the Company’s convertible promissory notes.

SCHEDULE OF FAIR VALUE MEASUREMENT

Balance at January 1, 2024	$	94,932,000
Accrued interest expense		159,305
Change in fair value		(48,468,678	)
Derecognition upon conversion of convertible promissory notes		(46,622,627	)
Balance at June 30, 2024	$	—

There were no transfers between levels during the six months ended June 30, 2025 and 2024.

The Company used the probability weighted expected return method valuation methodology to determine the fair value of the convertible promissory notes prior to the Merger. Significant assumptions and ranges used in determining the fair value of convertible promissory notes prior to the Merger include volatility (80%), discount rate (35% - 36%), and probability of a future liquidity event (85% - 95%). The Company used its stock price on the Closing Date to determine the fair value for the derecognition of the convertible promissory notes upon conversion on the Closing Date.

The Company recorded a gain on change in fair value of derivative warrant liabilities of $21,410 and $7,553 during the three and six months ended June 30, 2025, respectively. The Company recorded a loss on change in fair value of $38,788 and $6,815 during the three and six months ended June 30, 2024, respectively. The change in value during these periods was largely attributable to changes in the price of the underlying common stock and risk-free rates. During the fiscal year ended December 31, 2024, the Company acquired private warrants in connection with the Closing and issued written call options in connection with the Loan Agreement. The fair value of the written call options decreased to $0 between their issuance and December 31, 2024, and remained at $0 as of June 30, 2025. Accordingly, the written call options are not included in the tables below. Such fair value measurements are Level 3 inputs. The following table provides a roll-forward of the aggregate fair values of the warrants.

SCHEDULE OF FAIR VALUES OF WARRANTS

	Derivative warrant liabilities
Balance at January 1, 2024	$	—
Initial fair value at issuance		29,000
Change in fair value		(6,815	)
Balance at June 30, 2024	$	22,185

Balance at January 1, 2025	$	87,180
Change in fair value		7,553
Balance at June 30, 2025	$	94,733

The following table presents information about the Company’s liabilities that are measured at fair value on a recurring basis at June 30, 2025, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.

	Level		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level 3)
Liabilities:
Derivative warrant liabilities		3	$	—	$	—	$

SEC Form 10-Q filed by Tevogen Bio Holdings Inc.